Quantcast

Latest Non-sexuality Stories

2014-09-15 08:29:48

CHARLOTTE, N.C., Sept. 15, 2014 /PRNewswire/ -- At the Carolina Men's Clinic (http://thecarolinamensclinic.com/), Dr. Hansen and his staff treat men with erectile dysfunction every day, so they're in an excellent position to note the underlying factors influencing this condition. One such factor, the use of pharmaceuticals for treating high blood pressure, has become a focal point for the clinic. http://photos.prnewswire.com/prnvar/20140912/145822 "Erectile dysfunction often has a...

2014-09-05 23:03:47

Babatunde, M.D., sheds light on new, effective treatments for E.D. (PRWEB) September 05, 2014 Erectile dysfunction is often regarded as a taboo topic; something that people are ashamed to bring up in conversation. The frustration and the emotional aftermath surrounding this health issue causes anxiety, and unwelcomed stress in marriages, and in relationships. Author Dele Babatunde, M.D.’s new book, Erectile Dysfunction (ED) Is it a matter of the Heart? An early intervention approach,...

2014-08-11 16:25:18

LONDON, Aug. 11, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Male Hypoactive Sexual Desire Disorder-Pipeline Insights, 2014https://www.reportbuyer.com/product/2278643/-Male-Hypoactive-Sexual-Desire-Disorder-Pipeline-Insights-2014.html SUMMARYDelveInsight's," Male Hypoactive Sexual Desire Disorder-Pipeline Insights, 2014", report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the...

2014-05-20 08:34:24

Data show many women are not aware of hypoactive sexual desire disorder and often blame themselves for symptoms of low desire RED BANK, N.J., May 20, 2014 /PRNewswire/ -- Nearly one in two non-menopausal women ages 30 to 50 say they have experienced low sexual desire at some point in their lives, and many of these women (61%) felt distressed by it, according to a new national survey. Low sexual desire that is accompanied by distress and strains a woman's relationship with her...

2014-05-06 16:33:46

CRANBURY, N.J., May 6, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that data from a 12-week placebo-controlled dose-ranging study using self-administered subcutaneous bremelanotide for the treatment of female sexual dysfunction were presented at the American Psychiatric Association (APA) 2014 Annual Meeting in New York, NY on Tuesday, May 6, 2014 at 2:30 PM ET. APA is the world's largest psychiatric organization. Bremelanotide is a first-in-class,...

2014-04-29 08:35:16

CRANBURY, N.J., April 29, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that data from a 12-week placebo-controlled dose-ranging study using self-administered subcutaneous bremelanotide for the treatment of female sexual dysfunction were presented at the American College of Obstetricians and Gynecologists (ACOG) 2014 Annual Clinical Meeting in Chicago, IL on Monday, April 28, 2014 at 3:45 PM local time. ACOG is the nation's leading group of...

2014-03-31 09:43:07

Men suffering from sexual dysfunction can be successful at reversing their problem, by focusing on lifestyle factors and not just relying on medication, according to research at the University of Adelaide. In a new paper published in the Journal of Sexual Medicine, researchers highlight the incidence of erectile dysfunction and lack of sexual desire among Australian men aged 35-80 years. Over a five-year period, 31% of the 810 men involved in the study developed some form of erectile...

2014-03-27 23:01:03

Hypoactive Sexual Desire Disorder is often misunderstood and misdiagnosed. The multi-segment education initiative from Omnia Education aims to improve knowledge and awareness in healthcare professionals. Fort Washington, PA (PRWEB) March 27, 2014 More than 10% of premenopausal women may suffer from Hypoactive Sexual Desire Dysfunction (HSDD), and healthcare professionals often do not fully understand the disorder or misdiagnose patients. Omnia Education, the leading U.S. provider of...

2014-03-03 08:31:34

Orexa will be the first drug ever to enter clinical trials for male HSDD JERSEY CITY, N.J., March 3, 2014 /PRNewswire/ -- S1 Biopharma today announced its plan to initiate Phase 2a clinical trials in the third quarter of this year for Orexa (S1P-205), its first-in-class therapy to treat male Hypoactive Sexual Desire Disorder (HSDD). The double-blind placebo-controlled study will be the first to evaluate a drug for male HSDD. Key points: -- Hypoactive sexual desire disorder is a sexual...

2014-02-24 08:27:59

Data from first-in-class investigational treatment presented at the International Society for the Study of Women's Sexual Health (ISSWSH) Conference in San Diego CRANBURY, N.J., Feb. 24, 2014 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) presented new analyses from its Phase 2b clinical trial of bremelanotide, which demonstrated dose-dependent improvements in sexual desire and treatment satisfaction in premenopausal women with hypoactive sexual desire disorder (HSDD) and combined...


Word of the Day
virgule
  • A punctuation mark (/) used to separate related items of information.
  • A little rod; a twig.
This word comes from the Late Latin 'virgula,' accentual mark, a diminutive of 'virga,' rod.
Related